Aug 13, 2025 • Motley Fool
SOMEWHAT-BULLISH
ARS Pharma Sales Jump 3,040% in Q2
ARS Pharmaceuticals ( NASDAQ:SPRY ) , the biopharma company developing needle-free allergy treatments, released its second-quarter 2025 results on August 13, 2025. The most significant takeaway from the release was a major GAAP revenue beat, as total GAAP revenue climbed to $15.7 million versus ...
Aug 13, 2025 • Zacks Commentary
NEUTRAL
ARS Pharmaceuticals, Inc. ( SPRY ) Reports Q2 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -12.20% and +3.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 11, 2025 • Zacks Commentary
NEUTRAL
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 31, 2025 • Zacks Commentary
NEUTRAL
Corcept Therapeutics ( CORT ) Tops Q2 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of +26.09% and -4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 31, 2025 • Zacks Commentary
BULLISH
Here's What Could Help ARS Pharmaceuticals, Inc. ( SPRY ) Maintain Its Recent Price Strength
ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Jul 30, 2025 • Zacks Commentary
NEUTRAL
Catalyst Pharmaceutical ( CPRX ) Reports Next Week: Wall Street Expects Earnings Growth
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.